SI2839014T1 - Sestavek in postopki za zelo učinkovit prenos genov z uporabo variant kapside AAV-JA - Google Patents

Sestavek in postopki za zelo učinkovit prenos genov z uporabo variant kapside AAV-JA

Info

Publication number
SI2839014T1
SI2839014T1 SI201331862T SI201331862T SI2839014T1 SI 2839014 T1 SI2839014 T1 SI 2839014T1 SI 201331862 T SI201331862 T SI 201331862T SI 201331862 T SI201331862 T SI 201331862T SI 2839014 T1 SI2839014 T1 SI 2839014T1
Authority
SI
Slovenia
Prior art keywords
composition
methods
gene transfer
highly efficient
aav capsid
Prior art date
Application number
SI201331862T
Other languages
English (en)
Slovenian (sl)
Inventor
Mustafa N. Yazicioglu
Federico Mingozzi
Xavier Anguela
Katherine A. High
Original Assignee
The Children's Hospital Of Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Children's Hospital Of Philadelphia filed Critical The Children's Hospital Of Philadelphia
Publication of SI2839014T1 publication Critical patent/SI2839014T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/015—Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI201331862T 2012-04-18 2013-04-18 Sestavek in postopki za zelo učinkovit prenos genov z uporabo variant kapside AAV-JA SI2839014T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261635273P 2012-04-18 2012-04-18
US201361794995P 2013-03-15 2013-03-15
EP13778449.2A EP2839014B1 (en) 2012-04-18 2013-04-18 Composition and methods for highly efficient gene transfer using aav capsid variants
PCT/US2013/037170 WO2013158879A1 (en) 2012-04-18 2013-04-18 Composition and methods for highly efficient gene transfer using aav capsid variants

Publications (1)

Publication Number Publication Date
SI2839014T1 true SI2839014T1 (sl) 2021-05-31

Family

ID=49384070

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331862T SI2839014T1 (sl) 2012-04-18 2013-04-18 Sestavek in postopki za zelo učinkovit prenos genov z uporabo variant kapside AAV-JA

Country Status (26)

Country Link
US (2) US9909142B2 (cg-RX-API-DMAC10.html)
EP (1) EP2839014B1 (cg-RX-API-DMAC10.html)
JP (1) JP6342886B2 (cg-RX-API-DMAC10.html)
KR (1) KR102063483B1 (cg-RX-API-DMAC10.html)
CN (1) CN104487579B (cg-RX-API-DMAC10.html)
AU (1) AU2013249202B2 (cg-RX-API-DMAC10.html)
BR (2) BR112014025985A2 (cg-RX-API-DMAC10.html)
CA (1) CA2870736C (cg-RX-API-DMAC10.html)
CO (1) CO7200251A2 (cg-RX-API-DMAC10.html)
DK (1) DK2839014T3 (cg-RX-API-DMAC10.html)
ES (1) ES2862912T3 (cg-RX-API-DMAC10.html)
HU (1) HUE054087T2 (cg-RX-API-DMAC10.html)
IL (1) IL235102B (cg-RX-API-DMAC10.html)
IN (1) IN2014DN08812A (cg-RX-API-DMAC10.html)
MX (1) MX359518B (cg-RX-API-DMAC10.html)
MY (1) MY172457A (cg-RX-API-DMAC10.html)
NZ (1) NZ701693A (cg-RX-API-DMAC10.html)
PE (1) PE20150163A1 (cg-RX-API-DMAC10.html)
PH (1) PH12014502347B1 (cg-RX-API-DMAC10.html)
PL (1) PL2839014T3 (cg-RX-API-DMAC10.html)
PT (1) PT2839014T (cg-RX-API-DMAC10.html)
RU (1) RU2683497C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201406776TA (cg-RX-API-DMAC10.html)
SI (1) SI2839014T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013158879A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201407582B (cg-RX-API-DMAC10.html)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5702519B2 (ja) * 2005-04-07 2015-04-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖベクターの機能を上げる方法
CA2720097C (en) 2007-04-09 2016-07-19 University Of Florida Research Foundation, Inc. Raav vector compositions having tyrosine-modified capsid proteins and methods for use
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
CN117205331A (zh) 2011-04-29 2023-12-12 西莱克塔生物科技公司 用于降低抗体应答的致耐受性合成纳米载体
BR112014025985A2 (pt) 2012-04-18 2017-07-11 Childrens Hospital Philadelphia composição e métodos para transferência de gene altamente eficaz com o uso de variantes de capsídeo de aav
US12358954B2 (en) 2012-05-15 2025-07-15 University Of Florida Research Foundation, Incorporated Capsid-modified rAAV vector compositions and methods therefor
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
CN110639024A (zh) 2013-05-03 2020-01-03 西莱克塔生物科技公司 用于增强cd4+调节性t细胞的方法和组合物
ES2897508T3 (es) * 2013-05-31 2022-03-01 Univ California Variantes de virus adenoasociados y métodos de uso de las mismas
MX2016001044A (es) * 2013-07-22 2016-09-09 The Children's Hospital Of Philadelphia Aav variante y composiciones, metodos y usos para transferencia genica a celulas, organos y tejidos.
AU2014324717B2 (en) 2013-09-26 2020-10-08 University Of Florida Research Foundation, Inc. Synthetic combinatorial AAV capsid library for targeted gene therapy
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
US10308957B2 (en) 2014-03-04 2019-06-04 University Of Florida Research Foundation, Inc. rAAV vectors and methods for transduction of photoreceptors and RPE cells
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
BR112017001601A2 (pt) 2014-09-07 2017-11-21 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência antiviral de modulação da expressão genética
JP7023108B2 (ja) 2014-10-21 2022-02-21 ユニバーシティ オブ マサチューセッツ 組み換えａａｖバリアントおよびその使用
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
SG11201703281RA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
SG10202001102XA (en) 2014-11-14 2020-03-30 Voyager Therapeutics Inc Modulatory polynucleotides
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
WO2016126857A1 (en) 2015-02-03 2016-08-11 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
US10648000B2 (en) 2015-02-16 2020-05-12 University Of Florida Research Foundation, Incorporated rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes
WO2016134337A1 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Site-specific integrating recombinant aav vectors for gene therapy and improved production methods
JP6519080B2 (ja) * 2015-06-22 2019-05-29 ライオン株式会社 繊維製品用抗ウイルス組成物
KR102178322B1 (ko) 2015-06-23 2020-11-13 더 칠드런스 호스피탈 오브 필라델피아 변형된 인자 ix, 및 세포, 기관 및 조직으로 유전자를 전달하기 위한 조성물, 방법 및 용도
EP3831842A1 (en) 2015-09-28 2021-06-09 The University of North Carolina at Chapel Hill Methods and compositions for antibody-evading virus vectors
US12188037B2 (en) 2015-10-22 2025-01-07 University Of Florida Research Foundation, Incorporated Synthetic combinatorial AAV3 capsid library
EP4316512A3 (en) 2015-10-28 2024-04-24 The Trustees of The University of Pennsylvania Intrathecal administration of adeno-associated-viral vectors for gene therapy
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
AU2017248840B2 (en) 2016-04-16 2022-07-28 University Of Florida Research Foundation, Incorporated Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CN109476707B (zh) 2016-05-13 2022-12-02 4D分子治疗有限公司 腺相关病毒变体衣壳和其使用方法
JP7066635B2 (ja) 2016-05-18 2022-05-13 ボイジャー セラピューティクス インコーポレイテッド 調節性ポリヌクレオチド
WO2017201258A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
ES2863674T3 (es) * 2016-08-15 2021-10-11 Genzyme Corp Métodos para detectar AAV
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
WO2018071831A1 (en) 2016-10-13 2018-04-19 University Of Massachusetts Aav capsid designs
CN110325203A (zh) 2017-01-07 2019-10-11 西莱克塔生物科技公司 与合成纳米载体偶联的免疫抑制剂的模式化给药
US11028131B2 (en) * 2017-01-30 2021-06-08 Nippon Medical School Foundation Mutant of adeno-associated virus (AAV) capsid protein
EP3585883A4 (en) 2017-02-21 2021-04-14 University of Florida Research Foundation, Incorporated MODIFIED AAV CAPSID PROTEINS AND USES THEREOF
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
MX2019010757A (es) 2017-03-11 2020-01-20 Selecta Biosciences Inc Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
IL316259A (en) 2017-03-15 2024-12-01 Univ North Carolina Chapel Hill Polyploid gland associated with virus vectors and methods for preparing and using the same.
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
IL269534B2 (en) 2017-03-30 2025-01-01 Univ Queensland Chimeric molecules and their uses
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
AU2018261003A1 (en) 2017-05-05 2019-11-14 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's Disease
CA3066358A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. Enhancing agents for improved cell transfection and/or raav vector production
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN110461368A (zh) 2017-06-30 2019-11-15 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
US11497576B2 (en) 2017-07-17 2022-11-15 Voyager Therapeutics, Inc. Trajectory array guide system
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
EP3687561A4 (en) 2017-09-01 2021-06-09 The Australian National University "immunoregulatory molecules and uses therefor"
ES2948902T3 (es) 2017-09-20 2023-09-21 4D Molecular Therapeutics Inc Variantes de cápsides de virus adenoasociado y procedimientos de utilización de las mismas
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
CA3083472A1 (en) 2017-11-27 2019-05-31 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
CN111727243A (zh) 2017-12-19 2020-09-29 北卡罗来纳-查佩尔山大学 用于跨越血-脑屏障递送病毒载体的方法和组合物
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
JP2021512871A (ja) 2018-02-01 2021-05-20 ホモロジー・メディシンズ・インコーポレイテッド Ｐａｈ遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びそれらの使用方法
JP7244547B2 (ja) 2018-02-19 2023-03-22 ホモロジー・メディシンズ・インコーポレイテッド Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法
KR20200139679A (ko) 2018-02-26 2020-12-14 안톨알엑스, 인크. 면역관용성 리포솜 및 그의 사용 방법
MX2020008933A (es) * 2018-02-27 2021-01-15 Univ Pennsylvania Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
BR112020018354A2 (pt) * 2018-03-16 2020-12-29 Research Institute At Nationwide Children's Hospital Aumento de fornecimento gênico específico a tecido através de modificação de capsídeo
SG11202009450SA (en) 2018-04-03 2020-10-29 Stridebio Inc Virus vectors for targeting ophthalmic tissues
BR112020020266A2 (pt) 2018-04-03 2021-01-19 Stridebio, Inc. Vetores de vírus com evasão de anticorpos
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
BR112020020223A2 (pt) 2018-04-05 2021-01-19 Genethon Sorotipo de vírus adeno-associado híbrido recombinante entre aav9 e aavrh74 com tropismo pelo fígado reduzido
US12233136B2 (en) 2018-04-27 2025-02-25 Decibel Therapeutics, Inc. Myosin 15 promoters and uses thereof
WO2019210267A2 (en) * 2018-04-27 2019-10-31 Spark Therapeutics, Inc. Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
US12319929B2 (en) 2018-05-15 2025-06-03 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
WO2019222411A1 (en) * 2018-05-16 2019-11-21 Spark Therapeutics, Inc. Codon-optimized acid αlpha-glucosidase expression cassettes and methods of using same
KR20210034015A (ko) 2018-07-16 2021-03-29 셀렉타 바이오사이언시즈, 인크. Mma 구축물 및 벡터의 방법 및 조성물
WO2020018583A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
CN121160803A (zh) 2018-09-28 2025-12-19 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
BR112021006052A2 (pt) 2018-10-01 2021-09-08 Ultragenyx Pharmaceutical Inc. Terapia gênica para tratar acidemia propiônica
US11702673B2 (en) 2018-10-18 2023-07-18 University Of Florida Research Foundation, Incorporated Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス，インコーポレーテッド 第ｉｘ因子を発現するための組成物及び方法
JP7562544B2 (ja) 2019-02-08 2024-10-07 デシベル セラピューティクス インコーポレイテッド ミオシン１５プロモーター及びその使用
WO2020163743A1 (en) 2019-02-08 2020-08-13 Decibel Therapeutics, Inc. Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
CN113474461A (zh) 2019-02-25 2021-10-01 诺华股份有限公司 治疗bietti晶体营养不良的组合物和方法
CR20210444A (es) 2019-02-25 2021-11-02 Novartis Ag Composiciones y métodos para tratar distrofia cristalina de bietti
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
KR20220015425A (ko) 2019-05-28 2022-02-08 셀렉타 바이오사이언시즈, 인크. 약화된 항바이러스 전달 벡터 면역 반응을 위한 방법 및 조성물
RU2751592C2 (ru) 2019-08-22 2021-07-15 Общество С Ограниченной Ответственностью "Анабион" Выделенный модифицированный белок VP1 капсида аденоассоциированного вируса 5 серотипа (AAV5), капсид и вектор на его основе
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
TWI896570B (zh) * 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
EP4085255A1 (en) 2020-01-03 2022-11-09 Sarepta Therapeutics, Inc. Methods for analyzing aav capsid proteins
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
CN115151648A (zh) 2020-02-14 2022-10-04 阿尔特拉吉尼克斯制药公司 用于治疗cdkl5缺陷障碍的基因疗法
EP4121544A1 (en) 2020-03-19 2023-01-25 Ultragenyx Pharmaceutical Inc. Compositions and methods for reducing reverse packaging of cap and rep sequences in recombinant aav
EP4127189A1 (en) 2020-03-31 2023-02-08 Ultragenyx Pharmaceutical Inc. Gene therapy for treating propionic acidemia
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
BR112023003145A2 (pt) 2020-08-19 2023-05-09 Sarepta Therapeutics Inc Vetores de vírus adenoassociado para tratamento da síndrome de rett
AR123776A1 (es) 2020-10-15 2023-01-11 Hoffmann La Roche Construcciones de ácido nucleico para la activación simultánea de genes
CA3197730A1 (en) 2020-10-15 2022-04-21 F. Hoffman-La Roche Ag Nucleic acid constructs for va rna transcription
EP4274571A1 (en) 2021-01-05 2023-11-15 Selecta Biosciences, Inc. Viral vector dosing protocols
BR112023021495A2 (pt) * 2021-04-23 2023-12-19 Univ Florida Vetores aavrh74 para terapia gênica de distrofias musculares
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
AR126840A1 (es) 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en esta
PE20241995A1 (es) 2021-08-20 2024-09-27 Biocad Joint Stock Co Metodo para obtener una capside de virus adenoasociado modificada
AR126839A1 (es) 2021-08-20 2023-11-22 Llc «Anabion» Proteína de la cápside vp1 modificada aislada del virus adeno-asociado de serotipo 9 (aav9), cápside y vector basado en esta
US20230086710A1 (en) * 2021-09-14 2023-03-23 California Institute Of Technology Aav capsid variants
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
CN116554278A (zh) * 2022-01-30 2023-08-08 上海玮美基因科技有限责任公司 变异型腺相关病毒及其在疾病治疗中的应用
KR20240153391A (ko) 2022-03-07 2024-10-22 울트라제닉스 파마수티컬 인코포레이티드 변형된 뱃치 aav 생산 시스템 및 방법
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
IL316908A (en) * 2022-05-11 2025-01-01 Childrens Hospital Philadelphia Adeno-associated viral vectors for targeting deep brain structures
JP2025517987A (ja) 2022-05-23 2025-06-12 エフ． ホフマン－ラ ロシュ アーゲー Ａａｖ粒子血清型およびａａｖ粒子負荷状態の識別のためのラマンベースの方法
CA3258165A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag PROCESS FOR THE PRODUCTION OF RECOMBINED ADENOVIRUS-ASSOCIATED VIRUS (AAV) PARTICLES
AR129895A1 (es) 2022-07-14 2024-10-09 Hoffmann La Roche Método para producir partículas de aav recombinantes
CN120813689A (zh) 2022-08-11 2025-10-17 笛卡尔疗法股份有限公司 与免疫球蛋白蛋白酶及其融合体相关的组合物和方法
JP2025526697A (ja) 2022-08-15 2025-08-15 エフ． ホフマン－ラ ロシュ アーゲー 組換えウイルスベクターに関連する有害作用の予防または緩和
IL318766A (en) 2022-09-12 2025-04-01 Hoffmann La Roche Method for separating full and empty AAV particles
IL322001A (en) 2023-02-07 2025-09-01 Hoffmann La Roche Method for detecting antibodies to anti-AAV particles
EP4683676A1 (en) 2023-03-21 2026-01-28 F. Hoffmann-La Roche AG Method for the production of recombinant aav particle preparations
WO2024213596A1 (en) 2023-04-13 2024-10-17 F. Hoffmann-La Roche Ag Improved recombinant polyadenylation signal sequences and use thereof
WO2025057182A1 (en) * 2023-09-15 2025-03-20 Indian Institute Of Technology Kanpur Modified aav vectors for enhanced gene therapy in hemophilia b
WO2025082618A1 (en) 2023-10-20 2025-04-24 Fuse Vectors Aps In vitro parvovirus capsid manufacturing
WO2025168663A1 (en) 2024-02-09 2025-08-14 F. Hoffmann-La Roche Ag Method for producing recombinant adeno-associated viral particles
WO2025252480A1 (en) 2024-06-07 2025-12-11 F. Hoffmann-La Roche Ag Method for purifying plasmid dna

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1202962A (en) 1982-10-19 1986-04-08 David P. Clifford Substituted n-phenyl-n'-benzoyl ureas and their use as insecticides and acaricides
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
JP4888876B2 (ja) * 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
JP5702519B2 (ja) 2005-04-07 2015-04-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖベクターの機能を上げる方法
US9198984B2 (en) 2006-04-28 2015-12-01 The Trustees Of The University Of Pennsylvania Scalable production method for AAV
MX342858B (es) * 2010-03-29 2016-10-13 The Trustees Of The Univ Of Pennsylvania * Sistema de ablacion transgenica inducida farmacologicamente.
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
BR112014025985A2 (pt) 2012-04-18 2017-07-11 Childrens Hospital Philadelphia composição e métodos para transferência de gene altamente eficaz com o uso de variantes de capsídeo de aav

Also Published As

Publication number Publication date
PT2839014T (pt) 2021-03-19
JP2015514427A (ja) 2015-05-21
BR112014025985A2 (pt) 2017-07-11
NZ701693A (en) 2017-02-24
IL235102B (en) 2019-08-29
MY172457A (en) 2019-11-26
EP2839014A4 (en) 2015-12-30
HK1207663A1 (en) 2016-02-05
HUE054087T2 (hu) 2021-09-28
DK2839014T3 (da) 2021-03-08
CN104487579B (zh) 2022-01-18
EP2839014B1 (en) 2020-12-16
KR102063483B1 (ko) 2020-01-08
ZA201407582B (en) 2021-05-26
CA2870736A1 (en) 2013-10-24
WO2013158879A1 (en) 2013-10-24
PH12014502347A1 (en) 2014-12-22
AU2013249202A1 (en) 2014-11-06
KR20150004859A (ko) 2015-01-13
SG11201406776TA (en) 2015-03-30
RU2683497C2 (ru) 2019-03-28
US20180245098A1 (en) 2018-08-30
AU2013249202B2 (en) 2018-08-09
PH12014502347B1 (en) 2014-12-22
IN2014DN08812A (cg-RX-API-DMAC10.html) 2015-05-22
ES2862912T3 (es) 2021-10-08
JP6342886B2 (ja) 2018-06-13
MX359518B (es) 2018-10-01
US20150065562A1 (en) 2015-03-05
CO7200251A2 (es) 2015-02-27
PE20150163A1 (es) 2015-02-23
BR122021020419B1 (pt) 2023-01-17
US11279950B2 (en) 2022-03-22
EP2839014A1 (en) 2015-02-25
RU2014146159A (ru) 2016-06-10
CN104487579A (zh) 2015-04-01
MX2014012680A (es) 2015-05-11
PL2839014T3 (pl) 2021-08-23
CA2870736C (en) 2021-11-02
IL235102A0 (en) 2014-12-31
US9909142B2 (en) 2018-03-06

Similar Documents

Publication Publication Date Title
IL235102B (en) Compositions and methods for efficient gene transfer using aav caspid variants
SG10202007803QA (en) Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
DK2922554T3 (en) Terminalt modificeret rna
IL231983A0 (en) Dna containing tricyclo-phosphorothioate
ZA201409228B (en) Compositions and methods for modulating smn gene family expression
ZA201400563B (en) Axmi270 toxin gene and methods for its use
PT2539472E (pt) Pcr rápida para genotipagem de str
IL239480A0 (en) Improved transfer solution
EP2825647A4 (en) METHODS OF GENE REARRANGING
EP2934572A4 (en) FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
ZA201309516B (en) Protein matrix vaccine compositions including polycations
SG10201606946YA (en) Oligonucleotides for modulating gene expression and uses thereof
ZA201307363B (en) Axmi115 variant insecticidal gene and methods for its use
GB201206455D0 (en) Gene expression
ZA201303410B (en) Viral polymerase inhibitors
GB201214645D0 (en) Algal genome modification
IL235676A0 (en) Preparations and methods for regulating smn family gene expression
IL233445A0 (en) Methods and preparations for gene transfer
GB201106170D0 (en) Bacterial vaccine